

**Date:** May 21, 2025

**BSE Limited** 

Department of Corporate Services Pheroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

**SCRIP Code-544136** 

SYMBOL-RKSWAMY

Plot No. C/1, G Block

Exchange Plaza, 5th Floor,

**National Stock Exchange of India Limited** 

Bandra- Kurla Complex, Mumbai-400051

ISIN: INEONQ801033

<u>Subject: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015 ("SEBI Listing Regulations") - Submission of Press Release.</u>

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we are enclosing herewith a Press Release on Audited Financial Results (Standalone and Consolidated) of the R K SWAMY Limited for the quarter and financial year ended March 31, 2025.

This intimation is also being uploaded on the Company's website at www.rkswamv.com

This is for your information and records.

Thanking you

## For R K SWAMY Limited

APARNA Digitally signed by APARNA
PRASHANT PRASHANT BHAT Date: 2025.05.21 19:52:04 +05'30'

Aparna Bhat

**Company Secretary & Compliance Officer** 

Membership No.: A19995

Address: Esplanade House, 29, Hazarimal Somani Marg,

Fort, Mumbai 400 001



## R K SWAMY outlines nine major foundational steps taken in FY '25

Mumbai, May 21, 2025: R K Swamy Limited, the only Integrated Marketing Services provider listed on the main board of BSE/NSE, has unveiled several transformational steps across its service disciplines. These include the following: Launch of R K SWAMY Centre for Study of Indian Markets, original studies at scale to map viewership of Cricket, Study to measure the impact of advertising in Digital videos, Capacity to produce anamorphic videos for giant screens, application of AI in regular use as a tool in all disciplines, creation of a proprietary conversational AI solution called VARTA, 600-seat capacity expansion in the Customer Experience Centre, 346-seat capacity addition for Computer Aided Telephonic Interviews, ISO certification for Hansa Research, launch of Brand and Marketing Consulting Group, and scaling of its specialised service to the Pharmaceutical sector.

"We have made mindful and deliberate investments in all these areas with an eye on the future. We are pushing ahead on many fronts simultaneously as we see major opportunities in the market," said Shekar Swamy, MD and Group CEO, R K SWAMY Ltd.

The company posted a consolidated Total Income of Rs 306.15 crores for Fiscal 2025 compared to Rs 335.39 crores year ago, a decline of 8.7%. The consolidated PBT for the year was Rs 24.77 crores compared to Rs 53.57 crores, a year ago, decline of 53.8%.

"The decline in revenue is attributable to a few significant projects undertaken in the previous year which were in the nature of non-recurring projects. Notwithstanding this we have made fresh investments which had an impact on the current year's profitability. The management took a bold call to build capacity in many areas as outlined here. This is our confidence in what the future holds," said Rajeev Newar, Group CFO.

Disclaimer: Certain statements in this "Release" may not be based on historical information or facts and may be "forward looking statements" within the meaning of applicable securities laws and regulations, including, but not limited to, those relating to general business plans & strategy of the Company, its future outlook & growth prospects, future developments in its businesses, its competitive & regulatory environment and management's current views & assumptions which may not remain constant due to risks and uncertainties. Actual results could differ materially from those expressed or implied. The Company and its management assumes no responsibility to publicly amend, modify or revise any statement, based on any subsequent development, information, or events, or otherwise. The financial results are consolidated financials unless otherwise specified.